- Home
- RENB vs NSPR Comparison
RENB vs NSPR Comparison
Compare RENB & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- NSPR
- Stock Information
- Founded
- RENB 2011
- NSPR 2005
- Country
- RENB United States
- NSPR United States
- Employees
- RENB N/A
- NSPR N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- RENB Health Care
- NSPR Health Care
- Exchange
- RENB Nasdaq
- NSPR Nasdaq
- Market Cap
- RENB 73.5M
- NSPR 74.8M
- IPO Year
- RENB N/A
- NSPR N/A
- Fundamental
- Price
- RENB $0.31
- NSPR $2.43
- Analyst Decision
- RENB
- NSPR Strong Buy
- Analyst Count
- RENB 0
- NSPR 2
- Target Price
- RENB N/A
- NSPR $4.50
- AVG Volume (30 Days)
- RENB 1.8M
- NSPR 85.8K
- Earning Date
- RENB 05-15-2025
- NSPR 08-05-2025
- Dividend Yield
- RENB N/A
- NSPR N/A
- EPS Growth
- RENB N/A
- NSPR N/A
- EPS
- RENB N/A
- NSPR N/A
- Revenue
- RENB N/A
- NSPR $7,027,000.00
- Revenue This Year
- RENB N/A
- NSPR $4.85
- Revenue Next Year
- RENB N/A
- NSPR $113.47
- P/E Ratio
- RENB N/A
- NSPR N/A
- Revenue Growth
- RENB N/A
- NSPR 8.49
- 52 Week Low
- RENB $0.26
- NSPR $1.99
- 52 Week High
- RENB $2.10
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- RENB 48.33
- NSPR 52.46
- Support Level
- RENB $0.30
- NSPR $2.24
- Resistance Level
- RENB $0.35
- NSPR $2.55
- Average True Range (ATR)
- RENB 0.03
- NSPR 0.14
- MACD
- RENB 0.00
- NSPR 0.02
- Stochastic Oscillator
- RENB 46.77
- NSPR 59.51
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.